AngioSoma is now GlobeStar Therapeutics.
Our ticker symbol will change on Tuesday, July 5, 2021 to OTCBB: GSTC.
AngioSoma is a pioneer in the field of Multiple Sclerosis and other diseases. Our transformative therapies for the management of chronic neurodegenerative diseases are life-changing. Our patented therapies introduce a formulation of previously approved drugs which have been shown in clinical trials to improve the quality of life for these patients.
As a publicly traded company, AngioSoma, Inc. provides news on its operations through press release distributors like Business Wire, but it provides the same news here in an expanded format with links to all of the initial released locations and expanded images. This conforms to Regulation FD disclosure requirements.
Dr. Wisneski’s medical and teaching experience will play a key role in the growth of AngioSoma. RICHLAND, WA / ACCESSWIRE…
Penderghast’s Experience Medical Sciences Will Play a Key Role in the Growth of AngioSoma https://www.accesswire.com/viewarticle.aspx?id=641491&token=cvi2zoa141mfx13zf142 RICHLAND, WA / ACCESSWIRE /…
Croom’s Experience in Finance, Sales, and Operations Will Play a Key Role in the Growth of AngioSoma https://www.accesswire.com/viewarticle.aspx?id=641265&token=2x3hkvwnurme9np2m277 RICHLAND, WA…
AngioSoma, Inc., is an American biotechnology company originally organized in 2011, headquartered in Houston, Texas with offices in the State of Washington, focused on developing innovative therapies for people with serious and life-threating rare disorders. The Company patented and sold for $10 million of preferred shares a treatment for peripheral artery disease (PAD) called LiprostinTM followed by acquiring an exclusive license for a patented method of treating neurodegenerative diseases such as Multiple Sclerosis by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration and treating neurodegeneration. We are in discussions with several contract research organizations to assist with our submission of new drug application for global marketing.